Treatment for large granular lymphocytic leukaemia (LGLL)
Some people with large granular lymphocytic leukaemia (LGLL) may not need treatment. For those who do, treatment usually aims to control LGLL rather than cure it, but it is often effective. Find out about some of the common treatment options for LGLL.
Summary
- Many people with LGLL do not need treatment straight away. Instead, you will have regular check-ups and blood tests.
- If you need treatment, your team might recommend:
- Medicines that lower your immune system
- A clinical trial, if there is one suitable for you
- Surgery to remove your spleen, if it is swollen and causing symptoms
- Medicines to prevent or treat symptoms or side effects
- Side effects of some LGLL treatments include:
- A higher chance of getting infections
- Extreme tiredness (fatigue)
- Low blood cell counts or changes in your liver or kidney function
- Hair loss
- Your haematology team will monitor you closely so they can treat side effects promptly.
- You should not become pregnant, make someone pregnant or breastfeed while you are having treatment for LGLL
Who might need treatment for LGLL?
If LGLL is not causing symptoms, you may not need treatment straight away. You will usually start treatment if you have low levels of healthy blood cells or if you start to develop symptoms.
Between 3 and 5 in every 10 people with LGLL never need treatment. Between 5 and 7 in every 10 people with LGLL have treatment at some point.
If you need treatment, your team will base this on many factors, including:
- Whether or not you have any symptoms
- Your age and overall fitness
- Whether or not you have any other medical conditions
- The genetic changes in your leukaemia cells
- The proteins on the surface of your leukaemia cells
- Your preference on how you wish to be treated
Active monitoring
If your LGLL is not causing symptoms, you may not need treatment straight away. Instead, you might have regular check-ups and blood tests to monitor how LGLL is affecting you. This is called active monitoring. Some people call it watch and wait.
Active monitoring is a safe approach for slow-growing blood cancers. If you’re feeling well, there is no benefit to starting treatment before you need it. This means you can avoid the side effects of treatment for as long as possible. Treatment is still available when you need it.
You are likely to start treatment if:
- Your blood tests show low levels of healthy blood cells
- You start to develop symptoms or your symptoms become worse
Immunosuppressants
Most people with LGLL have medicines to lower the immune system. These are called immunosuppressants. You usually take them as tablets at home. They help improve your blood counts and reduce your symptoms. They may also reduce the number of abnormal lymphocytes in your body.
The main immunosuppressant medicines used to treat LGLL are:
- Methotrexate
- Cyclophosphamide
- Ciclosporin
Your haematology team will tell you what medicine they recommend, how to have it and what side effects you might get.
It can take at least 4 months to know if your treatment is working well.
Other treatments
Sometimes your haematology team might suggest different treatment. This could include:
- A clinical trial, if there is one suitable for you
- Surgery to remove your spleen, if it is swollen and causing symptoms
Supportive treatment
You might also need medicine to prevent or treat symptoms or side effects. This is called supportive treatment. It does not treat your LGLL itself, but it helps you feel better.
Supportive treatment might include:
- Blood transfusions or medicines called growth factors, if your blood counts are low
- Medicine to prevent or treat infections
- Medicine to prevent or treat side effects
- Steroids, which can help with many different symptoms
Monitoring during treatment
You will have regular blood tests during your treatment. Your team might also recommend other tests if needed. The tests check how well your LGLL is responding and how well your body is coping with the treatment.
If LGLL does not respond
Sometimes LGLL doesn’t respond well to treatment or comes back after treatment.
- Relapsed LGLL is when LGLL comes back after successful treatment.
- Refractory LGLL is when LGLL does not respond to your first treatment.
If this happens, your haematology team will talk to you about your treatment options. They might suggest:
- An antibody therapy such as rituximab or alemtuzumab. These are lab-made antibodies that stick to proteins on the surface of cancer cells. This helps your immune system recognise and destroy the cells. You usually have antibody therapy as an injection or through a drip.
- Chemotherapy medicines. These kill cells that are dividing rapidly, such as blood cells. If your doctor recommends chemotherapy, they will tell you what medicines they suggest and how you have them.
Possible side effects
Like all medicines, treatment for LGLL can cause side effects. Some of these can be serious. Side effects are different for everyone, and we cannot predict what side effects you may get.
Your haematology team will monitor you for serious side effects. You’ll have regular checks and blood tests. This means they can treat side effects promptly if they happen.
Tell your medical team straight away if you have any symptoms or side effects.
Your haematology team will explain the side effects you might get with your treatment. Here, we cover some of the important side effects of LGLL treatment in general. It is not a complete list.
Infection risk
LGLL treatment can lower your white blood cell count. This is called neutropenia. It means your body can’t fight infections as well as usual. So, you have a higher chance of getting infections, and any infections you do get may be more serious.
Infections can get worse quickly if you have a weakened immune system, so it is important to get treatment as soon as possible.
Contact your medical team straight away if you think you have an infection.
If your white blood cell count is low, there are things you can do to lower your risk of getting an infection. These include:
- Washing your hands frequently
- Avoiding crowded spaces
- Avoiding people who are unwell
- Storing and preparing food correctly to reduce the risk of food poisoning
- Making sure your kitchen is clean
- Regularly cleaning surfaces that you touch a lot, like light switches and door handles
- Having any vaccinations that you are eligible for
Your haematology team might also prescribe medicines to help prevent infections.
Fatigue
LGLL and its treatment can cause fatigue. This is a feeling of physical or mental exhaustion that doesn’t get better with sleep or rest.
Fatigue can be frustrating as it cannot be treated with medicines. But there are things you can do to help you manage it.
- Make plans and pace yourself.
- Prioritise things that are important to you and reserve energy for these.
- Build time to rest around planned busy periods.
- Allow yourself to rest as and when you need.
- Keep to a regular sleep schedule.
- Try to go to bed and wake up at around the same time each day.
- Keep your bedroom quiet and a comfortable temperature.
- Avoid eating or drinking alcohol, coffee, tea or chocolate before bedtime.
- Avoid using laptops, tablets or mobile phones before going to bed.
- Do regular, gentle exercise to maintain your fitness levels.
- Accept help with household tasks.
Make sure to tell your haematology team if you are experiencing fatigue. They may be able to suggest things to help or refer you for support if you need it.
Problems found on blood tests
You have regular blood tests during treatment to check your blood counts and your liver and kidney function.
- LGLL and its treatment can cause low blood counts. If this happens you might have blood transfusions or medicines called growth factors.
- LGLL can affect your liver and kidneys. If your blood tests find any problems, your team might reduce your dose or stop treatment for a while.
- LGLL can affect the level of fats in your blood.
Hair loss
Some treatments for LGLL can cause hair loss or thinning. Hair loss is usually temporary. It happens gradually. Some people prefer to shave their hair or cut it short. This can give you a feeling of control and reduce the emotional impact of it falling out. You could also cover your hair loss, if you choose too. There are lots of options like hats, headscarves, wraps, turbans or wigs.
Cancer Hair Care UK has more information on hair loss, including how to care for Afro-textured hair during chemotherapy.
Pregnancy, fertility and breastfeeding
Some treatments for LGLL may affect your fertility. If you think you may want to have children in the future, tell your haematology team. They can give you advice on sperm or egg storage before starting treatment.
- Treatment for LGLL may harm unborn babies. Some treatments can damage sperm and eggs. You should not get pregnant, or make someone pregnant, while you are having treatment for LGLL.
- If you could get pregnant or make someone pregnant, you must use effective contraception during treatment and for several months after. It depends on what treatment you are having. Your team will tell you.
- Treatment for LGLL passes into breastmilk. You must not breastfeed during treatment.
Sources we used to develop this information
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul;36(7):1720-48.
Couette N, Jarjour W, Brammer JE, Simon Meara A. Pathogenesis and treatment of T-large granular lymphocytic leukemia (T-LGLL) in the setting of rheumatic disease. Frontiers in Oncology. 2022 Jun 7;12:854499.
El-Sharkawi D, Attygalle A, Dearden C. Mature T-cell leukemias: challenges in diagnosis. Frontiers in Oncology. 2022 Mar 9;12:777066.
Fox CP, Ahearne MJ, Pettengell R, Dearden CE, El-Sharkawi D, Kassam S, Cook L, Cwynarski K, Illidge T, Collins G. Guidelines for the management of mature T-and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. British Journal of Haematology| BJH. 2022 Feb;196(3):507-22.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Davé UP, Dogan A, Foss F, Frosch Z, Goodman AM, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Pan D, Rajguru SA, Riedell P, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Stephany M, Thornton S, Torres-Cabala C, Wilcox R, Wu P, Zain J, Zhang Y, Dwyer S, Sundar H. NCCN Clinical Practice Guidelines in Oncology: T-cell Lymphomas. National Comprehensive Cancer Network. 2024.
Rahul E, Ningombam A, Acharya S, Tanwar P, Ranjan A, Chopra A. Large granular lymphocytic leukemia: a brief review. American Journal of Blood Research. 2022 Feb 15;12(1):17.
Thames Valley Cancer Alliance and Oxford University Hospitals NHS Foundation Trust. Protocol: Methotrexate Oral [Internet]. 2024. Available from https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-87-methotrexate-weekly.pdf [Accessed Mar 2025].
Ullah F, Markouli M, Orland M, Ogbue O, Dima D, Omar N, Mustafa Ali MK. Large granular lymphocytic leukemia: clinical features, molecular pathogenesis, diagnosis and treatment. Cancers. 2024 Mar 27;16(7):1307.
Zawit M, Bahaj W, Gurnari C, Maciejewski J. Large granular lymphocytic leukemia: from immunopathogenesis to treatment of refractory disease. Cancers. 2021 Sep 1;13(17):4418.
Need support?
You are not alone. We're here for you whether you have a diagnosis yourself or know someone who has. If you'd like advice, support, or a listening ear, call our freephone helpline on 08088 010 444 or send a WhatsApp message to 07500 068 065.
Help us improve our information
We aim to provide information that’s reliable, up-to-date, and covers what matters to you. Please complete our short survey to help us improve our information and make sure it meets your needs.
About our information
This information is aimed at people in the UK. We do our best to make sure it is accurate and up to date but it should not replace advice from your health professional. Find out more about our information.
Page last reviewed: 30 June 2025
Updated January 2026
Next review due: 30 June 2028
More information
About large granular lymphocytic leukaemia (LGLL)
Large granular lymphocytic leukaemia (LGLL) is a slow-growing blood cancer. It starts in white blood …
Active monitoring
Slow-growing, chronic blood cancers may not need treatment immediately after diagnosis. Instead, you may go …
Support and community
Leukaemia Care support people affected by leukaemia, myelodysplastic syndromes and myeloproliferative neoplasms. Find out about …
A to Z of leukaemia: what the words mean
Being diagnosed with leukaemia can be overwhelming. You might read or hear medical terms that …
Need help understanding this information?
Our support team is here to answer your questions and provide guidance.
Contact Support